Treatment for mitochondrial disorders

医学 粒线体疾病 梅德林 临床试验 呼吸链 疾病 心理干预 线粒体呼吸链 内科学 重症监护医学 儿科 物理疗法 线粒体DNA 精神科 线粒体 生物化学 化学 生物 政治学 法学 基因 细胞生物学
作者
Gerald Pfeffer,Kari Majamaa,Douglass M. Turnbull,David R. Thorburn,Patrick F. Chinnery
出处
期刊:The Cochrane library [Elsevier]
被引量:229
标识
DOI:10.1002/14651858.cd004426.pub3
摘要

Background Mitochondrial respiratory chain disorders are the most prevalent group of inherited neurometabolic diseases. They present with central and peripheral neurological features usually in association with other organ involvement including the eye, the heart, the liver, and kidneys, diabetes mellitus and sensorineural deafness. Current treatment is largely supportive and the disorders progress relentlessly causing significant morbidity and premature death. Vitamin supplements, pharmacological agents and exercise therapy have been used in isolated cases and small clinical trials, but the efficacy of these interventions is unclear. The first review was carried out in 2003, and identified six clinical trials. This major update was carried out to identify new studies and grade the original studies for potential bias in accordance with revised Cochrane Collaboration guidelines. Objectives To determine whether there is objective evidence to support the use of current treatments for mitochondrial disease. Search methods We searched the Cochrane Neuromuscular Disease Group Specialized Register (4 July 2011), CENTRAL (2011, Issue 2, MEDLINE (1966 to July 2011), and EMBASE (January 1980 to July 2011), and contacted experts in the field. Selection criteria We included randomised controlled trials (including cross‐over studies). Two of the authors independently selected abstracts for further detailed review. Further review was performed independently by all five authors to decide which trials fit the inclusion criteria and graded risk of bias. Participants included males and females of any age with a confirmed diagnosis of mitochondrial disease based upon muscle histochemistry, respiratory chain complex analysis of tissues or cell lines or DNA studies. Interventions included any pharmacological agent, dietary modification, nutritional supplement, exercise therapy or other treatment. The review authors excluded studies at high risk of bias in any category. The primary outcome measures included an change in muscle strength and/or endurance, or neurological clinical features. Secondary outcome measures included quality of life assessments, biochemical markers of disease and negative outcomes. Data collection and analysis Two of the authors (GP and PFC) independently identified studies for further evaluation from all abstracts within the search period. For those studies identified for further review, all five authors then independently assessed which studies met the entry criteria. For the included studies, we extracted details of the number of randomised participants, treatment, study design, study category, allocation concealment and other risk of bias criteria, and participant characteristics. Analysis was based on intention‐to‐treat data. We planned to use meta‐analysis, but this did not prove necessary. Main results The authors reviewed 1335 abstracts, and from these identified 21 potentially eligible abstracts. Upon detailed review, 12 studies fulfilled the entry criteria. Of these, eight were new studies that had been published since the previous version of this review. Two studies which were included in the previous version of this review were excluded because of potential for bias. The comparability of the included studies is extremely low because of differences in the specific diseases studied, differences in the therapeutic agents used, dosage, study design, and outcomes. The methodological quality of included studies was generally high, although risk of bias was unclear in random sequence generation and allocation concealment for most studies. Otherwise, the risk of bias was low for most studies in the other categories. Serious adverse events were uncommon, except for peripheral nerve toxicity in a long‐term trial of dichloroacetate (DCA) in adults. One trial studied high‐dose coenzyme Q10 without clinically meaningful improvement (although there were multiple biochemical, physiologic, and neuroimaging outcomes, in 30 participants). Three trials used creatine monohydrate alone, with one reporting evidence of improved measures of muscle strength and post‐exercise lactate, but the other two reported no benefit (total of 38 participants). One trial studied the effects of a combination of coenzyme Q10, creatine monohydrate, and lipoic acid and reported a statistically significant improvement in biochemical markers and peak ankle dorsiflexion strength, but overall no clinical improvement in 16 participants. Five trials studied the effects of DCA: three trials in children showed a statistically significant improvement in secondary outcome measures of mitochondrial metabolism (venous lactate in three trials, and magnetic resonance spectroscopy (MRS) in one trial; total of 63 participants). One trial of short‐term DCA in adults demonstrated no clinically relevant improvement (improved venous lactate but no change in physiologic, imaging, or questionnaire findings, in eight participants). One longer‐term DCA trial in adults was terminated prematurely due to peripheral nerve toxicity without clinical benefit (assessments included the GATE score, venous lactate and MRS, in 30 participants). One trial using dimethylglycine showed no significant effect (measurements of venous lactate and oxygen consumption (VO2) in five participants). One trial using a whey‐based supplement showed statistically significant improvement in markers of free radical reducing capacity but no clinical benefit (assessments included the Short Form 36 Health Survey (SF‐36) questionnaire and UK Medical Research Council (MRC) muscle strength, in 13 participants). Authors' conclusions Despite identifying eight new trials there is currently no clear evidence supporting the use of any intervention in mitochondrial disorders. Further research is needed to establish the role of a wide range of therapeutic approaches. We suggest further research should identify novel agents to be tested in homogeneous study populations with clinically relevant primary endpoints.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
车紫霜完成签到,获得积分10
1秒前
SYLH应助yongtao采纳,获得10
1秒前
董涛完成签到,获得积分10
4秒前
科研通AI5应助xiaxue采纳,获得10
4秒前
充电宝应助Anyemzl采纳,获得10
4秒前
pw发布了新的文献求助50
5秒前
雾影觅光发布了新的文献求助10
5秒前
yar应助科研鸟采纳,获得10
5秒前
CC发布了新的文献求助10
5秒前
muyingleng完成签到,获得积分10
6秒前
隐形曼青应助强健的冰棍采纳,获得10
6秒前
研友_nV2pkn发布了新的文献求助10
7秒前
大个应助iiiid采纳,获得10
7秒前
微笑访枫完成签到,获得积分20
8秒前
完美世界应助小李叭叭采纳,获得10
8秒前
8秒前
QZZ发布了新的文献求助10
8秒前
8秒前
桐桐应助yingqing采纳,获得10
9秒前
9秒前
呆萌枕头完成签到,获得积分10
10秒前
yongtao完成签到,获得积分10
10秒前
科研通AI5应助wxt采纳,获得10
12秒前
12秒前
simey发布了新的文献求助10
12秒前
14秒前
gujian发布了新的文献求助10
14秒前
16秒前
Ava应助小任性采纳,获得10
16秒前
专注的乐荷给专注的乐荷的求助进行了留言
16秒前
英俊的铭应助Diffileft采纳,获得10
17秒前
18秒前
Zzz完成签到,获得积分10
18秒前
端庄蚂蚁完成签到,获得积分10
19秒前
19秒前
19秒前
科研通AI2S应助啦啦啦采纳,获得10
20秒前
Oil完成签到,获得积分10
20秒前
20秒前
Hello应助雾影觅光采纳,获得10
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971078
求助须知:如何正确求助?哪些是违规求助? 3515742
关于积分的说明 11179305
捐赠科研通 3250852
什么是DOI,文献DOI怎么找? 1795501
邀请新用户注册赠送积分活动 875868
科研通“疑难数据库(出版商)”最低求助积分说明 805207